Zoledronate to help prevent Paget’s disease over time
Part of Bones, joints & muscles clinical trials.
This trial is a long-term follow-up for people who already took part in a previous study called ZiPP. It tests whether continuing treatment with zoledronate can help prevent Paget’s disease from developing or worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the earlier ZiPP study
- You are willing and able to sign an informed consent form
- You are willing and able to follow the study plan and visit schedule
- You must be able to understand the study well enough to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
This study checks how the body handles a medicine called zoledronic acid in people with kidney disease who are on dialysis and have weak bones (osteoporosis). It may help doctors find the right dose to safely treat bone loss in this group.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
Hear when a new Paget Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.